Get started
Neurocrine Biosciences, Inc.NN

Neurocrine Biosciences, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

NBIX trade ideas

Neurocrine Stock Quote | Chart & Forecast SummaryKey Indicators On Trade Set Up In General 1. Push Set Up 2. Range Set up 3. Break & Retest Set Up Notes On Session # Neurocrine Stock Quote - Double Formation * 155.00 USD | 1st Area Of Value | Subdivision 1 * A+ Set Up)) | Completed Survey - Triple Formation * 130.00 USD | 2nd Area Of Value | Subdivision 2 * 012345 | Wave Count & Entry Bias | Subdivision 3 * Daily Time Frame | Trend Settings Condition Active Sessions On Relevant Range & Elemented Probabilities; European Session(Upwards) - US-Session(Downwards) - Asian Session(Ranging) Conclusion | Trade Plan Execution & Risk Management On Demand; Overall Consensus | Buy
CAPITALCOM:NBIXLong
by TradePolitics
Neurocrine Stock Quote | Chart & Forecast SummaryKey Indicators On Trade Set Up In General 1. Push Set Up 2. Range Set up 3. Break & Retest Set Up Notes On Session # Neurocrine Stock Quote - Double Formation * Retracement | Not Numbered | A+ Set Up Area | Subdivision 1 * Wedge Structure | 117.00 USD & 106.00 USD | Subdivision 2 - Triple Formation * Bottom Structure | Uptrend Bias At 0.5 & 0.382 * Target Entry | Bottom Structure | Survey Valid * Daily Time Frame | Zone | Subdivision 3 Active Sessions On Relevant Range & Elemented Probabilities; London(Upwards) - NYC(Downwards) Conclusion | Trade Plan Execution & Risk Management On Demand; Overall Consensus | Buy
CLong
by TradePolitics
Solid Growth but Misses Q2 Earnings TargetsNeurocrine Biosciences Inc. (NASDAQ: NBIX) is continuing to advance its position in the biotech sector, despite facing a slight setback in its Q2 2024 earnings report. The company posted revenue of $590.2 million, which was higher than analyst estimates of $545.9 million, representing a 30.4% year-over-year increase. However, earnings per share (EPS) came in at $0.63, missing expectations of $1.15 due to increased operational costs. Growth Prospects and Drivers The company’s robust pipeline, which focuses on treatments for neurological, neuroendocrine, and neuropsychiatric disorders, continues to be its primary growth driver. Its top-performing product, Ingrezza, used for treating tardive dyskinesia, remains a key revenue generator. Analysts remain optimistic, with price targets ranging from $170 to $189, reflecting confidence in the company’s strategic advancements. Market Sentiment and Future Outlook Although the recent earnings miss caused some market volatility, the long-term outlook remains strong. Neurocrine Biosciences continues to gain traction with new research programs and FDA approvals, positioning it well for future growth. Analysts predict a full-year EPS of $4.22. For investors, Neurocrine offers an attractive opportunity in the biotech space, especially with its growing portfolio and continued focus on innovative therapies. NOT TRADING ADVICE. ALWAYS DO YOUR OWN RESEARCH.
NLong
by olimchik
(Potential Trade) NBIX(13 May 2024) Disclaimer: All information posted are the author's own trades/potential trades. The author is not a certified Financial Advisor and do not have the certifications to provide financial advice. These information are strictly for educational purposes only and do not constitute any financial, investment or trading advice of any form. Please do your own research (DYOR) before taking any investment/trading actions. The author will not be liable for any legal liabilities or responsibilities due to actions taken by any reader of these postings. Counter has been consolidating sideways in the form of a Triangle which appears to be nearing its completion. Potential Entry: $145.22 Initial S/L: $130.13 Trade will be voided if prices break down in the opposite direction instead
NLong
by ElliotWaveTrades
"NBIX Stock Breaks All-Time Highs, Strong Buy Opportunity!"NBIX Stock Breaks All-Time Highs: A Strong Buy Opportunity Emerges Neurocrine Biosciences Inc. (NBIX) is currently making waves in the stock market as it breaks out of its all-time highs, signaling a promising opportunity for investors. After 14 years of steady upward momentum and price consolidation, NBIX appears poised for further growth, with technical indicators suggesting a bullish trend ahead. The recent surge in NBIX's stock price comes on the heels of strong performance and positive sentiment surrounding the company's products and pipeline. With a focus on innovative treatments for neurological and endocrine disorders, Neurocrine Biosciences has established itself as a leader in the biopharmaceutical industry, attracting investors seeking exposure to high-growth sectors. Technical analysis reveals that NBIX's current breakout is accompanied by the formation of a bull flag pattern, a bullish continuation pattern that often precedes further upward movement. This consolidation phase following a prolonged uptrend suggests that NBIX may be gearing up for another leg higher, providing an attractive entry point for investors. To capitalize on this potential opportunity, traders are advised to monitor the 4-hour time frame closely, watching for confirmation of the breakout and additional upside momentum. A sustained move above the current resistance levels could signal further strength in NBIX's stock price, potentially leading to a retest of its previous all-time highs. Investors considering a position in NBIX should also keep an eye on key support levels and market dynamics, as volatility in the broader market could impact the stock's trajectory. However, with a strong track record of growth and a robust pipeline of innovative therapies, NBIX appears well-positioned to weather any short-term fluctuations and deliver long-term value to shareholders. In conclusion, Neurocrine Biosciences Inc. is breaking out of its all-time highs, presenting a compelling buying opportunity for investors. With 14 years of upward momentum behind it and a bullish pattern forming, NBIX looks poised for further growth in the coming weeks and months. By monitoring the 4-hour time frame and remaining vigilant for additional breakouts, investors can position themselves to capitalize on the potential upside in NBIX's stock price.
NLong
by UnknownUnicorn2319099
Neurocrine Biosciences (NBIX: NASDAQ)Neurocrine Biosciences (NBIX), a biotech company specializing in treatments for neurological, endocrine, and psychiatric disorders, is poised for opportunities in congenital adrenal hyperplasia (CAH). Analysts project NBIX to potentially achieve worldwide revenue of $660 million by fiscal year 2030, emphasizing substantial market potential. Crinecerfont, an NBIX drug, has shown a positive impact, allowing 63% of adults to lower their glucocorticoid doses. With a 77% boost in EBIT and a robust free quarterly cash flow of $280.80 million, NBIX demonstrates financial strength. The bullish outlook on NBIX suggests a favorable stance above $99.00-$100.00, with an upside target set at $150.00-$155.00.
NLong
by Richtv_official
NBIX: Pharma higher highs!Neurocrine Biosciences, Inc. Intraday - We look to Buy at 104.23 (stop at 98.97) A sequence of intraday higher highs and lows has been posted. This is positive for sentiment and the uptrend has potential to return. A weaker opening is expected to challenge bullish resolve. Support is located at 104.00 and should stem dips to this area. Dip buying offers good risk/reward. Our profit targets will be 120.54 and 128.00 Resistance: 121.00 / 136.00 / 140.00 Support: 104.00 / 80.00 / 55.00 Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Signal Centre’) . Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Signal Centre.
NLong
by VantageMarkets
NBIX Breakout TradeNBIX is in the biotech sector which I have been highlighting for several months as one of the strongest areas in the market. After emerging from a textbook breakout pattern in early August, shares have consolidated in a tight handle formation. If you look at the relative strength line at the top of the chart, you will notice three pink dots over the last several days. These show the RS line making new highs. Although the stock drifted sideways, the rest of the market has been in an ugly correction, so NBIX is actually holding up better than most other names. I'm looking for a breakout on volume above its down sloping trendline.
NLong
by rossgivens
Bottom FishingNBIX snapped up after hitting a new yearly low and falling below the bands set on an 80 SMA. Price returns to the bands on this setting eventually. When price is over the bands on this setting, then it will usually go down to settle back inside the bands. (orange arrow at top) Price being below the bands exhibits a lot of selling pressure, but when selling is exhausted, then there are buyers. Large volume bar earlier in the year marked with a green star. I know I did not generate that massive volume (o: so I guesstimate someone would come back in and save the investment they made that day. I could be wrong about that but just seems so. I know I would! I do not think I would want to be in NBIX at earnings as it does not look like they meet the numbers. I am watching this one, but I bought a tiny bit yesterday. Something told me to hold my horses and be a bit more confident. PE 31.77 EPS 2.84 and looks like revenue grows quarter to quarter. Short interest is 4.44%. Much of the Biotech sector is at or close to it's bottom. Stocks like GH and the ETF, XBI seem to be settling down "Ingrezza prescriptions really depend upon face-to-face visits with prescribing physicians, and COVID-19 restrictions further hamper the company's sales and physician education efforts." So news I see on this one is on the negative side, as I suppose that due to the political virus, some there will no longer be face to face doctor visits?? Is not seeing your doctor in person considered healthy? Dunno about that one but it is what it is. No recommendation. Don't forget to take a look in the rearview mirror (o: Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson’s disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington’s disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for treating rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company’s products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for treating anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
N
by lauralea
PAY to NEUROCRINE BIOSCIENCES DailyHey my friends, NEUROCRINE BIOSCIENCES is in a bearish fake movement with a return of traded buy volume and a large hammer candle upside down On TIMEFRAME M1 we see a dash with a large buy volume issued it came test and the highest of the bollinger to go to the top of the stabilization zone and test it. Big potential to breakout the price at the same time the zone for arriving in a new one and going on the next higher (seen on MULTI TIMEFRAME H4 and H1). Little buying force to test half of the intermediate median of ANDREWS PITCHFORK. Please LIKE & FOLLOW, thank you!
NShort
by stephanelibatd
2